Charles R. Harrington

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

Claude M. Wischik, Patricia C. Edwards, Robert Lai et al. · Proceedings of the National Academy of Sciences · 1996 · 541 citations

Life Sciences, Neurobiology, Neuroscience +17

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

Serge Gauthier, Howard Feldman, Lon S. Schneider et al. · The Lancet · 2016 · 416 citations · Full text

Medicine, Neurology, Pharmacology +14

Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease

Claude M. Wischik, Roger T. Staff, Damon Wischik et al. · Journal of Alzheimer s Disease · 2015 · 258 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

Gordon Wilcock, Serge Gauthier, Giovanni B. Frisoni et al. · Journal of Alzheimer s Disease · 2017 · 217 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Staging of Cytoskeletal and β-Amyloid Changes in Human Isocortex Reveals Biphasic Synaptic Protein Response during Progression of Alzheimer’s Disease

Elizabeta B. Mukaetova‐Ladinska, Francisco Garcia-Siera, Herman J. Gertz et al. · American Journal Of Pathology · 2000 · 188 citations · Full text

Life Sciences, Neurobiology, Neuroscience +14